Clinical trials: Palsy Supranuclear
Multiple System Atrophy, Parkinson Disease
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
This is a non-interventional observational study designed to systematically record the results of routine laryngeal examinations and specific characteristics of dysphagia in patients with neurodegenerative disorders.
- Conditions
- Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy, Motor Neuron Disease
- Trial name
- FEEMSA (NCT04706234)
- Where
- 16 sites in Austria, Germany and 6 more
- Volunteers
- 350 people
- Sponsor
- Kliniken Beelitz GmbH
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug…
- Conditions
- Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP)
- Trial name
- 4RTNI-2 (NCT02966145)
- Testing
- Observational Study
- Where
- 8 sites in United States, Canada
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Progressive Supranuclear Palsy
A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.
This study intends to study the safety and tolerance of the combination of pyruvate, creatine, and niacinamide over 6 months in patients with PSP.
- Trial name
- NCT00605930
- Testing
- Pyruvate, creatine, niacinamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Progressive Supranuclear Palsy, Corticobasal Degeneration
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
Drug therapy of atypical parkinsonism is generally considered either ineffective or minimal 1. Therefore, there is an urgent need to find alternative therapies to treat atypical parkinsonian disorders.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonism
- Trial name
- NCT01174771
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT04658199
- Testing
- UCB0107 (bepranemab)
- Where
- 11 sites in Belgium, Germany and 2 more
- Volunteers
- 19 people
- Sponsor
- UCB Biopharma SRL
Progressive Supranuclear Palsy, Neurological Disorders
Effects of Coenzyme Q10 in PSP and CBD
To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).
- Trial name
- NCT00532571
- Testing
- CoQ10
- Where
- United States
- Sponsor
- Lahey Clinic
Idiopathic Parkinson's Disease, Progressive Supranuclear Palsy
Robot Walking Rehabilitation in Parkinson's Disease
The effectiveness of non-pharmacological treatment on gait impairment on Parkinson Disease (PD) such as exercises has been demonstrated; in particular an example for patient tailored exercises is physiotherapy.
- Trial name
- ROBOPARK (NCT01668407)
- Testing
- Robot-Assisted Gait Training (RAGT), Treadmill Gait Training (TT)
- Where
- 3 sites in Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS San Raffaele Roma
Progressive Supranuclear Palsy, Parkinsonism
tDCS Plus Physical Therapy for Progressive Supranuclear Palsy
Objective of the study: To test the efficacy of cerebellar transcranial direct current stimulation (tDCS) associated with physical rehabilitation on postural instability and falls in progressive supranuclear palsy using a…
- Conditions
- Progressive Supranuclear Palsy, Parkinsonism, Parkinsonian Disorders
- Trial name
- NCT04237948
- Testing
- transcranial direct current stimulation (tDCS), Physical therapy
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Europea di Ricerca Biomedica Ferb Onlus
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Multiple System Atrophy, Dementia With Lewy Bodies (DLB)
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and…
- Conditions
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- NCT07805967
- Testing
- We did not apply any interventions; only observational research was conducted.
- Where
- 20 sites in China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Progressive Supranuclear Palsy (PSP)
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
- Trial name
- NCT03413319
- Testing
- ABBV-8E12
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- AbbVie
Progressive Supranuclear Palsy, Corticobasal Degeneration
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
- Trial name
- NCT02167594
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Healthy Volunteers
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).
- Conditions
- Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
- Trial name
- NCT03058965
- Testing
- [18F]MNI-958, [18F]Florbetapir, DaTscan
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Progressive Supranuclear Palsy, Cortical Basal Ganglionic Degeneration
tDCS as Treatment for Motor Function
Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation.
- Conditions
- Progressive Supranuclear Palsy, Cortical Basal Ganglionic Degeneration, Parkinson Disease
- Trial name
- PSP (NCT07291687)
- Testing
- Transcranial direct current stimulation (TDCS), Stimulation Arm
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Baycrest
Multiple System Atrophy, Progressive Supranuclear Palsy
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus'…
- Trial name
- NCT00211224
- Testing
- Riluzole
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- King's College London
Parkinsonian Syndromes, Parkinson's Disease
Biomarkers in Parkinsonian Syndromes
Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by the abnormal accumulation of…
- Conditions
- Parkinsonian Syndromes, Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- BIOPARK (NCT02114242)
- Testing
- CSF, blood and urine sampling, clinical measures of disease severity and progression
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA)
UPenn Observational Research Repository on Neurodegenerative Disease
The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
- Conditions
- Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Amyotrophic Lateral Sclerosis(ALS)
- Trial name
- UNICORN (NCT04715399)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Progressive Supranuclear Palsy
Risk Factors for Progressive Supranuclear Palsy (PSP)
Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by…
- Trial name
- NCT00431301
- Where
- 10 sites in United States, Canada
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Progressive Supranuclear Palsy
Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP)
The purpose of this cohort study is to develop a reliable biomarker in progressive nuclear palsy (PSP).
- Trial name
- SCAN-PSP (NCT05579301)
- Where
- 2 sites in South Korea
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Alzheimer Disease, Mild Cognitive Impairment
Tau Imaging With JNJ067
This protocol is designed to assess the utility of a new positron emission tomography (PET) radiopharmaceutical to image tau, [18F] JNJ067, invented by Janssen Pharmaceutical companies of Johnson \& Johnson.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Progressive Supranuclear Palsy
- Trial name
- NCT03926702
- Testing
- Radiopharmaceuticals
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley